SCHEMBL564901

SCHEMBL564901

Nc1cccc(-c2ccc(N)c(O)c2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.71
ALOX15 P16050 2/20 0.71
HSD17B10 Q99714 2/20 0.71
MCL1 Q07820 1/20 0.56
MAOA P21397 1/20 0.56
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA9 Q16790 2/20 0.52
APP P05067 1/20 0.50
MAP4K4 O95819 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 2/20 0.48
KDM4E B2RXH2 1/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 1/20 0.48
HSP90AA1 P07900 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16949848 0.89 ALOX15 (0.81) CYP3A4ALOX15HSD17B10MCL1CA12
SCHEMBL29488305 0.89 ALOX15 (0.81) CYP3A4ALOX15HSD17B10MCL1CA12
SCHEMBL8063212 0.85 APP (0.71) CYP3A4ALOX15HSD17B10MCL1MAOA
SCHEMBL23924225 0.84 CYP3A4 (1.00) CYP3A4ALOX15HSD17B10APPALDH1A1
SCHEMBL105866 0.84 CYP3A4 (1.00) CYP3A4ALOX15HSD17B10APPALDH1A1
SCHEMBL29365557 0.84 CYP3A4 (1.00) CYP3A4ALOX15HSD17B10APPALDH1A1
SCHEMBL29549758 0.84 CYP3A4 (1.00) CYP3A4ALOX15HSD17B10APPALDH1A1
SCHEMBL565190 0.83 ALDH1A1 (0.70) CYP3A4ALOX15HSD17B10MCL1MAOA
SCHEMBL564219 0.83 CYP3A4 (0.71) CYP3A4ALOX15HSD17B10APPMAP4K4
SCHEMBL565193 0.83 ALOX15 (0.77) CYP3A4ALOX15HSD17B10MCL1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674029-B2 Method of preparing stabilized polymeric systems using polymeric peroxides Sunocs LLC (US) 2014-03-18 US disclosed
US-20120035307-A1 PROCESS FOR MAKING STABLIZED POLYMERIC SYSTEMS WITH NANOSTRUCTURES SONG CHENGQIAN (US) 2012-02-09 US disclosed
US-20120035315-A1 METHOD OF PREPARING STABLIZED POLYMERIC SYSTEMS USING POLYMERIC PEROXIDES SONG CHENGQIAN (US) 2012-02-09 US disclosed
US-7498467-B2 Antioxidant and bisaminophenol derivative IDEMITSU KOSAN CO., LTD. (JP) 2009-03-03 US disclosed
US-20080161608-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2008-07-03 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed
US-20060208227-A1 Antioxidant and bisaminophenol derivative IDEMITSU LOSAN CO., LTD (JP) 2006-09-21 US disclosed
EP-1612254-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161608-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE CBR1, CBR3, HMOX1 CYP3A4 360/4885ALOX15 1352/4885HSD17B10 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.